
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SNX5 CRISPR/Cas9 KO Plasmid (h) | sc-404660 | 20 µg | $397.00 |
Human SNX5 (sorting nexin 5) encodes a PX domain–containing endosomal protein that binds phosphoinositides and cooperates with membrane remodeling factors to regulate cargo sorting and vesicular trafficking. SNX5 participates in endosome-to-Golgi and endosomal recycling routes, supporting receptor turnover and signal attenuation by controlling the subcellular localization of transmembrane proteins. Through its roles in endosomal tubulation and protein complex assembly, SNX5 influences cellular homeostasis processes linked to receptor-mediated signaling, nutrient uptake, and membrane composition. Altered endosomal trafficking pathways involving sorting nexins are associated with dysregulated growth factor signaling and cellular stress responses, making SNX5 relevant to mechanistic studies of disease-associated trafficking defects.
SNX5 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SNX5 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SNX5 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SNX5 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SNX5 protein expression.
This CRISPR knockout system enables efficient generation of SNX5-deficient cell models for investigation of SNX5 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.